Important Update: Potential for Additional Doses in Pfizer COVID-19 Vaccine Vials

Special Bulletin

The Food and Drug Administration (FDA) last week granted an emergency use authorization (EUA) to Pfizer, Inc. for its BNT162b2 mRNA COVID-19 vaccine. As you are aware, distribution and administration of the first shipments are well underway across the country.

In light of new information, the FDA Center for Biologics Evaluation and Research Prevention has indicated that it is now acceptable to use every full dose obtainable from each product vial. Initially, the EUA issued for this product authorized five doses per vial. However, given the public health emergency there is the potential for a sixth and potential seventh dose from each of the vials. The federal government is expected to make a formal announcement.

As you make the determination as to whether you can obtain additional doses from a vial, please consider the following:

• The remaining liquid in a vial must make up a full dose;
• Do not pool from multiple vials to create an additional dose, as this product is preservative free; and
• Consult your state’s department of health if you have questions about any state-wide policies pertaining to this issue.

Next Steps

Visit AHA’s website to review a host of resources on COVID-19 vaccines and therapeutics, including materials on distribution and workforce issues.

Further Questions

If you have questions, please contact AHA at 800-424-4301.